Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Cost-effectiveness and budget impact analysis of Daratumumab, Lenalidomide and dexamethasone for relapsed-refractory multiple myeloma

Abstract Background The prominent efficacy in terms of increasing progression-free survival (PFS) of Daratumumab, Lenalidomide and dexamethasone (DRd) triplet therapy versus Carfilzomib, Lenalidomide and dexamethasone (KRd) was proven previously in relapsed-refractory multiple myeloma (RRMM). Howeve...

Full description

Bibliographic Details
Main Authors: Zahra Goudarzi, Rahil Sadat Shahtaheri, Zhila Najafpour, Haleh Hamedifar, Hamidreza Ebrahimi
Format: Article
Language:English
Published: BMC 2024-02-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Daratumumab
Carfilzumib
Cost effectiveness analysis
Multiple myeloma
Online Access:https://doi.org/10.1186/s12962-024-00525-4

Internet

https://doi.org/10.1186/s12962-024-00525-4

Similar Items